MXPA02010430A - Inhibidores aminotransferasa dependientes de aminoacidos de cadena ramificada y su uso en el tratamiento de las enfermedades neurodegenerativas. - Google Patents
Inhibidores aminotransferasa dependientes de aminoacidos de cadena ramificada y su uso en el tratamiento de las enfermedades neurodegenerativas.Info
- Publication number
- MXPA02010430A MXPA02010430A MXPA02010430A MXPA02010430A MXPA02010430A MX PA02010430 A MXPA02010430 A MX PA02010430A MX PA02010430 A MXPA02010430 A MX PA02010430A MX PA02010430 A MXPA02010430 A MX PA02010430A MX PA02010430 A MXPA02010430 A MX PA02010430A
- Authority
- MX
- Mexico
- Prior art keywords
- treating
- disease
- neurodegenerative diseases
- treatment
- amino acid
- Prior art date
Links
- 230000004770 neurodegeneration Effects 0.000 title abstract 3
- 208000015122 neurodegenerative disease Diseases 0.000 title abstract 2
- 239000002380 aminotransferase inhibitor Substances 0.000 title 1
- 150000005693 branched-chain amino acids Chemical class 0.000 title 1
- 230000001419 dependent effect Effects 0.000 title 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 206010002091 Anaesthesia Diseases 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 101710105312 Branched-chain-amino-acid aminotransferase Proteins 0.000 abstract 1
- 101710097328 Branched-chain-amino-acid aminotransferase, cytosolic Proteins 0.000 abstract 1
- 101710194298 Branched-chain-amino-acid aminotransferase, mitochondrial Proteins 0.000 abstract 1
- 208000000094 Chronic Pain Diseases 0.000 abstract 1
- 206010010904 Convulsion Diseases 0.000 abstract 1
- 206010048843 Cytomegalovirus chorioretinitis Diseases 0.000 abstract 1
- 206010011878 Deafness Diseases 0.000 abstract 1
- 206010012689 Diabetic retinopathy Diseases 0.000 abstract 1
- 201000010374 Down Syndrome Diseases 0.000 abstract 1
- 208000010412 Glaucoma Diseases 0.000 abstract 1
- 208000023105 Huntington disease Diseases 0.000 abstract 1
- 208000013016 Hypoglycemia Diseases 0.000 abstract 1
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 101710158343 Probable branched-chain-amino-acid aminotransferase Proteins 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 101710199693 Putative branched-chain-amino-acid aminotransferase Proteins 0.000 abstract 1
- 206010044688 Trisomy 21 Diseases 0.000 abstract 1
- 206010046543 Urinary incontinence Diseases 0.000 abstract 1
- 230000002411 adverse Effects 0.000 abstract 1
- 239000002647 aminoglycoside antibiotic agent Substances 0.000 abstract 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 abstract 1
- 230000037005 anaesthesia Effects 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- AZPBDRUPTRGILK-UHFFFAOYSA-N benzotriazol-1-ium-1-ylidenemethanediamine;4-methylbenzenesulfonate Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1.C1=CC=C2N(C(=N)N)N=NC2=C1 AZPBDRUPTRGILK-UHFFFAOYSA-N 0.000 abstract 1
- 230000019771 cognition Effects 0.000 abstract 1
- 230000036461 convulsion Effects 0.000 abstract 1
- 208000001763 cytomegalovirus retinitis Diseases 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 239000003257 excitatory amino acid Substances 0.000 abstract 1
- 230000002461 excitatory amino acid Effects 0.000 abstract 1
- 230000010370 hearing loss Effects 0.000 abstract 1
- 231100000888 hearing loss Toxicity 0.000 abstract 1
- 208000016354 hearing loss disease Diseases 0.000 abstract 1
- 230000002218 hypoglycaemic effect Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 208000014674 injury Diseases 0.000 abstract 1
- 208000028867 ischemia Diseases 0.000 abstract 1
- 206010027599 migraine Diseases 0.000 abstract 1
- 208000004296 neuralgia Diseases 0.000 abstract 1
- 208000021722 neuropathic pain Diseases 0.000 abstract 1
- 238000001356 surgical procedure Methods 0.000 abstract 1
- 230000008733 trauma Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Virology (AREA)
- Endocrinology (AREA)
- Addiction (AREA)
- Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Communicable Diseases (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
Abstract
La invencion se relaciona a inhibidores BCAT y al uso de los mismos para tratar o prevenir pérdida neuronal asociada con apoplejía, isquemia, trauma por SNC, hipoglicemia y cirugía, así como para tratar enfermedades neurodegenerativas incluyendo enfermedad de Alzheimer, esclerosis lateral amiotrofica, enfermedad de Huntington y síndrome de Down, para tratar o prevenir las consecuencias adversas de la sobreestimulacion de Ios aminoácidos excitadores, tratar ansiedad, psicosis, convulsiones, pérdida de audicion inducida por antibioticos aminoglicosidos, migrafia, dolor cronico, dolor neuropático, enfermedad de Parkinson, retinopatía diabética, glaucoma, retinitis por CMV, incontinencia urinaria, tolerancia o retiro de opioide exogeno y anestesia inducida, así como para cognicion incrementada.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33359301P | 2001-11-27 | 2001-11-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA02010430A true MXPA02010430A (es) | 2003-06-02 |
Family
ID=23303445
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA02010430A MXPA02010430A (es) | 2001-11-27 | 2002-10-22 | Inhibidores aminotransferasa dependientes de aminoacidos de cadena ramificada y su uso en el tratamiento de las enfermedades neurodegenerativas. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US6632831B2 (es) |
| EP (1) | EP1314426B1 (es) |
| JP (1) | JP2003183264A (es) |
| AT (1) | ATE317696T1 (es) |
| AU (1) | AU2002351011A1 (es) |
| BR (1) | BR0206327A (es) |
| CA (1) | CA2412624A1 (es) |
| DE (1) | DE60209192T2 (es) |
| MX (1) | MXPA02010430A (es) |
| WO (1) | WO2003045384A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100384828C (zh) * | 2005-05-08 | 2008-04-30 | 山东大学 | (z)-5-[[(3,5-二叔丁基)-4-羟基苯基]亚甲基]-2-亚氨基-4-噻唑啉酮甲磺酸盐的制备方法 |
| EP2481801A1 (en) | 2011-01-28 | 2012-08-01 | Deutsches Krebsforschungszentrum | Inhibitors of branched-chain-aminotransferase-1 (BCAT1) for the treatment of neoplasia |
| US20140206667A1 (en) | 2012-11-14 | 2014-07-24 | Michela Gallagher | Methods and compositions for treating schizophrenia |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4775677A (en) * | 1985-05-13 | 1988-10-04 | Warner-Lambert Company | [3-substituted-2-(substituted imino)-4-oxo-5-thiazolidinylidene]acetic acids having activity as leukotriene antagonists |
| US5143928A (en) * | 1990-03-27 | 1992-09-01 | Warner-Lambert Company | 3,5-di-tertiarybutyl-4-hydroxyphenylmethylene derivatives of 2-substituted thiazolidinones, oxazolidinones, and imidazolidinones as antiinflammatory agents |
| US5554767A (en) * | 1993-05-21 | 1996-09-10 | Warner-Lambert Company | Alpha-mercaptoacrylic acid derivatives having calpain inhibitory activity |
| JPH07285952A (ja) * | 1994-04-08 | 1995-10-31 | Fujisawa Pharmaceut Co Ltd | 新規複素環誘導体 |
| DZ3141A1 (fr) * | 1999-12-08 | 2001-01-14 | Warner Lambert Co | Inhibiteurs d'aminotransferase acides aminés-dépendante à chaîne ramifiée, et leur utilisation dans le cadre du traitement de la rétinopathie diabétique. |
| MXPA03001277A (es) * | 2000-09-19 | 2004-07-30 | Warner Lambert Co | Inhibidores de aminotransferasa dependientes de aminoacido de cadena ramificada y su uso en el tratamiento de enfermedades neurodegenerativas. |
-
2002
- 2002-10-22 MX MXPA02010430A patent/MXPA02010430A/es unknown
- 2002-11-11 AU AU2002351011A patent/AU2002351011A1/en not_active Abandoned
- 2002-11-11 WO PCT/IB2002/004727 patent/WO2003045384A1/en not_active Ceased
- 2002-11-13 EP EP02257797A patent/EP1314426B1/en not_active Expired - Lifetime
- 2002-11-13 DE DE60209192T patent/DE60209192T2/de not_active Expired - Fee Related
- 2002-11-13 AT AT02257797T patent/ATE317696T1/de not_active IP Right Cessation
- 2002-11-22 BR BR0206327-1A patent/BR0206327A/pt not_active IP Right Cessation
- 2002-11-25 CA CA002412624A patent/CA2412624A1/en not_active Abandoned
- 2002-11-26 US US10/305,094 patent/US6632831B2/en not_active Expired - Fee Related
- 2002-11-27 JP JP2002344312A patent/JP2003183264A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2003045384A1 (en) | 2003-06-05 |
| JP2003183264A (ja) | 2003-07-03 |
| DE60209192T2 (de) | 2006-11-16 |
| BR0206327A (pt) | 2003-11-18 |
| DE60209192D1 (de) | 2006-04-20 |
| CA2412624A1 (en) | 2003-05-27 |
| US20030162779A1 (en) | 2003-08-28 |
| EP1314426A9 (en) | 2003-09-17 |
| EP1314426A1 (en) | 2003-05-28 |
| US6632831B2 (en) | 2003-10-14 |
| AU2002351011A1 (en) | 2003-06-10 |
| ATE317696T1 (de) | 2006-03-15 |
| EP1314426B1 (en) | 2006-02-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA02010231A (es) | Inhibidores aminotransferasa dependientes de aminoacidos de cadena ramificada y su uso en el tratamiento de las enfermedades neurodegenerativas. | |
| IL168365A (en) | Use of a rasagaline with or without riluzole for preparing a medicament for treating amyotrophic lateral sclerosis | |
| BR0108547A (pt) | Derivados de aminoadamantano como agentes terapêuticos | |
| ZA97991B (en) | Novel cyclic amino acids as pharmaceutical agents. | |
| IL125544A0 (en) | Novel substituted cyclic amino acids as pharmaceutical agents | |
| ZA972199B (en) | Novel bridged cyclic amino acids as pharmaceutical agents. | |
| MXPA03001277A (es) | Inhibidores de aminotransferasa dependientes de aminoacido de cadena ramificada y su uso en el tratamiento de enfermedades neurodegenerativas. | |
| ZA972496B (en) | Substituted 2,3-benzodiazepin-4-ones and the use thereof. | |
| EP1983000A3 (en) | Method for the treatment of multiple sclerosis by inhibiting IL-17 activity | |
| WO2007087151A3 (en) | Combination of ache inhibitor and 5-ht6 antagonist for the treatment of cognitive dysfunction | |
| ATE359794T1 (de) | 3, 7 thiaprostansäurederivate als mittel zur verminderung des augeninnendruckes | |
| DE60234919D1 (de) | 3, 7 oder 3 und 7 thia- oder oxaprostansäure derivate als mittel zur senkung des augeninnendrucks | |
| WO2001068053A3 (en) | Methods and compositions for treating and preventing posterior segment ophthalmic disorders | |
| AU4673300A (en) | Amino heterocycles useful as pharmaceutical agents | |
| MXPA02010430A (es) | Inhibidores aminotransferasa dependientes de aminoacidos de cadena ramificada y su uso en el tratamiento de las enfermedades neurodegenerativas. | |
| HUT64841A (en) | Process and composition for treating eyes | |
| MXPA02011921A (es) | Inhibidores de dipeptidasa acida n-acetilada-alfa-enlazada para el tratamiento de trastornos retinianos y glaucona. | |
| WO2006002096A3 (en) | Low doses of l-citrulline for treating diseases | |
| ATE506061T1 (de) | Zusammensetzungen und verfahren zur behandlung, kontrolle, verminderung, verbesserung bzw. prävention von allergien | |
| WO2023107630A3 (en) | Amino alcohol compounds and uses thereof | |
| NO20045089L (no) | Substituerte aminoalkanfosfonsyrer for behandling av neuropatisk smerte, affektive og oppmerksomhetsforstyrrelser, schizofreni, tinnitus, myopi og andre okulaere lidelser | |
| WO2008057599A3 (en) | Methods for the treatment of abeta related disorders and compositions therefor | |
| MX2022012252A (es) | Metodos para tratar la enfermedad de alzheimer. | |
| WO2008027345A3 (en) | COMBINED γ-SECRETASE INHIBITOR AND PHENOTHIAZINE DERIVATIVE TREATMENT OF NEURODEGENERATIVE DISEASES | |
| BR0303209A (pt) | Composição farmacêutica para o tratamento de incontinência urinária feminina |